Priorities & Actions
Parkinson's Plan 2006
Parkinson's Matrix
Research Agenda

Research Resources

Animal Models

Antibody Resources
Clinical Research
Gene Therapy
Genetic Resources
Brain Banks Across the
   United States

Funding Research
Funding Announcements
Clinical Trials
Related Literature

Research Centers
NIH Intramural Research
Udall Centers of
   Excellence

Patient/Caregiver Information
Parkinson's Disease
PD Clinical Trials

Contact Us
My Privacy

NINDS is part of the
National Institutes of
Health

Download Adobe Reader

  Print-friendly version

   Email this page

Join our electronic mailing list

Drosophila Models

Gene	Promoter	Phenotype	Availability	Reference
Human α-synuclein: WT, A53T, A30P	Gal4 dcd-Gal4	Eye abnormality. α-synuclein filamentous inclusions. Loss of dopamine neurons by TH immunoassay. Progressive loss of motor activity via climbing assay.	Contact Mel Feany: Mel_feany@hms.harvard.edu	Feany M.B and Bender W.W. (2000). A drosophila model of Parkinson's disease. Nature 404 (6776), 394-8. [abstract]
Human α-synuclein: WT, A53T, A30P	dcd-Gal4	Eye abnormality. α-synuclein inclusions. Dopaminergic neuron loss, reversible by Hsp70 coexpression.	Nancy Bonini, U. Penn.	Auluck PK, Chan HY, Trojanowski JQ, Lee VM, and Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002, February 1; 295(5556): 809-10. [abstract]
Human Tau:WT, R406W, V337M	Elav-Gal4	Cell death in cortex, vacuolar histology. Lack of aggregate formation. Early death.	Contact Mel Feany: Mel_feany@hms.harvard.edu	Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, and Feany MB. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001 Jul 27; 293(5530): 711-714. [abstract]

Last updated February 09, 2005